A Multi-center, Single Arm, Safety and Efficacy Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation in Subjects With Relapsed or Refractory Peripheral T-cell Lymphoma

Trial Profile

A Multi-center, Single Arm, Safety and Efficacy Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation in Subjects With Relapsed or Refractory Peripheral T-cell Lymphoma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Nov 2017

At a glance

  • Drugs Pralatrexate (Primary) ; Folic acid; Vitamin B12 analogues
  • Indications Anaplastic large cell lymphoma; Peripheral T-cell lymphoma
  • Focus Therapeutic Use
  • Sponsors Mundipharma (China) Pharmaceutical
  • Most Recent Events

    • 23 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top